Skip to main content

Efgartigimod alfa Pregnancy and Breastfeeding Warnings

Medically reviewed by Last updated on Apr 12, 2022.

Efgartigimod alfa is also known as: Vyvgart

Efgartigimod alfa Pregnancy Warnings

Animal studies have failed to reveal evidence of adverse effects on embryofetal development in either rat or rabbits with doses up to 10 times the recommended human dose administered during organogenesis. Administration to rats throughout gestation and lactation did not show adverse effects on pre- or postnatal development. This drug is a monoclonal antibody and monoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Benefit should outweigh risk.

US FDA pregnancy category: Not assigned.

Risk summary: There are no data on the use of this drug during pregnancy; animal data has not shown evidence of adverse developmental outcomes.

-Because this drug is expected to reduce maternal immunoglobulin G (IgG) antibody levels, a reduction in passive protection to the newborn is anticipated; risk and benefits should be considered prior to administering live or live attenuated vaccines to infants exposed to this drug in utero.

See references

Efgartigimod alfa Breastfeeding Warnings

Benefit should outweigh risk.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

-There is no information available on the presence in human milk, the effects on the breastfed infant, or the effects on milk production; maternal immunoglobulin G (IgG) is known to be present in human milk.
-Developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for this drug and any potential adverse effects on the breastfed infant from this drug or from the underlying maternal condition.

See references

References for pregnancy information

  1. "Product Information. Vyvgart (efgartigimod alfa)." argenx US Inc. (2022):

References for breastfeeding information

  1. "Product Information. Vyvgart (efgartigimod alfa)." argenx US Inc. (2022):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.